CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial. by BY CARL ZIMMER


The results were a blow to hopes that the vaccine could help meet the world’s urgent need. “This is pretty devastating” for the company, one expert said.

Published: June 16, 2021 at 10:44PM

from NYT Health https://ift.tt/2S4aRhB